Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.

Jereb M, Kotar T.

Wien Klin Wochenschr. 2006 Apr;118(5-6):170-4.

PMID:
16773483
2.

Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin.

Niederman MS.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S127-32. doi: 10.1086/591393. Review.

3.

[Diagnostic utility of procalcitonin in community-acquired respiratory tract infections--a literature review].

Wróblewski T, Marcisz C, Kurzawska G.

Postepy Hig Med Dosw (Online). 2004;58:495-505. Review. Polish.

4.

Serum markers in community-acquired pneumonia and ventilator-associated pneumonia.

Póvoa P.

Curr Opin Infect Dis. 2008 Apr;21(2):157-62. doi: 10.1097/QCO.0b013e3282f47c32. Review.

PMID:
18317039
5.

Biomarkers in community-acquired pneumonia.

Krüger S, Welte T.

Expert Rev Respir Med. 2012 Apr;6(2):203-14. doi: 10.1586/ers.12.6. Review.

PMID:
22455492
6.

[Procalcitonin as an indicator of infection in patients with liver cirrhosis].

Husová L, Husa P, Senkyrík M, Lata J.

Vnitr Lek. 2004 Feb;50(2):153-6. Review. Czech.

PMID:
15077592
7.

The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review.

Berg P, Lindhardt BØ.

Dan Med J. 2012 Mar;59(3):A4357. Review.

PMID:
22381083
8.

[The diagnostic value of procalcitonin in severe sepsis].

Andrejaitiene J.

Medicina (Kaunas). 2006;42(1):69-78. Review. Lithuanian.

9.

Making sense of scoring systems in community acquired pneumonia.

Niederman MS.

Respirology. 2009 Apr;14(3):327-35. Review.

PMID:
19353770
10.

What cardiologists do need to know about procalcitonin.

Mueller C, Christ-Crain M, Müller B.

Clin Lab. 2005;51(1-2):1-4. Review.

PMID:
15719698
11.

Diagnostic strategies for healthcare-associated pneumonia.

Polverino E, Torres A.

Semin Respir Crit Care Med. 2009 Feb;30(1):36-45. doi: 10.1055/s-0028-1119807. Epub 2009 Feb 6. Review.

PMID:
19199185
12.

[Investigations for etiologic causes in community-acquired pneumonia in children (besides imagery)].

Le Roux P.

Arch Pediatr. 1998;5 Suppl 1:28s-32s. Review. French.

PMID:
10223159
13.

The role of procalcitonin in community-acquired pneumonia: a literature review.

Lee M, Snyder A.

Adv Emerg Nurs J. 2012 Jul-Sep;34(3):259-71. doi: 10.1097/TME.0b013e318261338d. Review.

PMID:
22842969
14.

[Role of C-reactive protein in the diagnosis, prognosis and follow-up of community-acquired pneumonia].

Bauer S, Lamy O.

Rev Med Suisse. 2010 Nov 3;6(269):2068-70, 2072-3. Review. French.

PMID:
21140960
15.

Prediction of prognosis by markers in community-acquired pneumonia.

Viasus D, Simonetti A, Garcia-Vidal C, Carratalà J.

Expert Rev Anti Infect Ther. 2013 Sep;11(9):917-29. doi: 10.1586/14787210.2013.825442. Review.

PMID:
24053273
16.

Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia?

Upadhyay S, Niederman MS.

Infect Dis Clin North Am. 2013 Mar;27(1):19-31. doi: 10.1016/j.idc.2012.11.003. Epub 2012 Dec 6. Review.

PMID:
23398863
17.

Procalcitonin for guidance of antibiotic therapy.

Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B.

Expert Rev Anti Infect Ther. 2010 May;8(5):575-87. doi: 10.1586/eri.10.25. Review.

PMID:
20455686
18.

[Procalcitonin: a reliable marker for the diagnosis and monitoring of the course of bacterial infection].

Holub M, Rozsypal H, Chalupa P.

Klin Mikrobiol Infekc Lek. 2008 Dec;14(6):201-8. Review. Czech.

PMID:
19214953
19.

[Procalcitonin as a marker of severe bacterial infection in children].

Schrøder H, Lodahl D.

Ugeskr Laeger. 2004 Oct 18;166(43):3804-7. Review. Danish. No abstract available.

PMID:
15544109
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk